These drugs act on various metabolic targets, including LXRα, ACC, diacylglycerol O-acyltransferase 2 (DGAT2), FASN, FXR, and fibroblast growth factors (FGFs), to regulate lipid synthesis, breakdown, and transport, thereby improving metabolic abnormalities associated with fatty liver disease. This evidence concerns the gene NR1H3 and fatty liver disease.